Treatment of Pneumonia with Respiratory Distress

Initial Assessment and Management

Patients with pneumonia and respiratory distress should be classified as having severe pneumonia requiring intensive care unit (ICU) or intermediate care, with immediate initiation of appropriate intravenous antibiotics, according to the European Respiratory Society 1, 3
Antibiotic treatment should be initiated immediately after diagnosis to reduce mortality, as recommended by the Infectious Diseases Society of America 4
Respiratory distress indicates severe disease requiring intravenous antibiotic administration, with a non-antipseudomonal cephalosporin III plus a macrolide OR a respiratory fluoroquinolone as first-line therapy, according to the European Society of Clinical Microbiology and Infectious Diseases 2, 3
Low molecular weight heparin should be given to patients with acute respiratory failure, as suggested by the American Thoracic Society 3

For severe community-acquired pneumonia without risk factors for Pseudomonas aeruginosa, first-line options include a non-antipseudomonal third-generation cephalosporin (ceftriaxone or cefotaxime) PLUS a macrolide, or moxifloxacin or levofloxacin, as recommended by the Infectious Diseases Society of America 1, 2, 5
For severe community-acquired pneumonia with risk factors for Pseudomonas aeruginosa, antipseudomonal cephalosporin (e.g., cefepime) OR acylureidopenicillin/β-lactamase inhibitor (e.g., piperacillin-tazobactam) OR carbapenem (meropenem preferred) should be used, plus either ciprofloxacin OR a macrolide with an aminoglycoside, according to the European Society of Clinical Microbiology and Infectious Diseases 1, 2, 3

Early mobilization for all patients when possible, and non-invasive ventilation should be considered, particularly in patients with COPD and ARDS, as recommended by the American Thoracic Society 3
Treatment of severe sepsis and septic shock with appropriate supportive measures, including fluid resuscitation and vasopressor support, should be provided, according to the Surviving Sepsis Campaign 3
Steroids are not recommended in the routine treatment of pneumonia, as stated by the Infectious Diseases Society of America 3

Treatment duration should generally not exceed 8 days in a responding patient, with biomarkers, particularly procalcitonin (PCT), guiding shorter treatment duration, as recommended by the Infectious Diseases Society of America 2
Switch to oral treatment after reaching clinical stability is safe even in patients with severe pneumonia, according to the European Society of Clinical Microbiology and Infectious Diseases 3

Response should be monitored using simple clinical criteria: body temperature, respiratory and hemodynamic parameters, with C-reactive protein measured on days one and three/four, especially in patients with unfavorable clinical parameters, as recommended by the European Respiratory Society 3
Two types of treatment failures should be differentiated: non-responding pneumonia (first 72 hours) and slowly resolving pneumonia, according to the Infectious Diseases Society of America 3

For patients with influenza-associated pneumonia during flu season, antiviral therapy should be added, as recommended by the Centers for Disease Control and Prevention 5
For community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infection, add vancomycin or linezolid, according to the Infectious Diseases Society of America 5

Delaying antibiotic administration - antibiotics should be initiated immediately after diagnosis, as emphasized by the Infectious Diseases Society of America 4
Failing to reassess non-responding patients - non-response within 72 hours may indicate antimicrobial resistance or incorrect diagnosis, according to the European Society of Clinical Microbiology and Infectious Diseases 3
Overlooking the need for supportive care - respiratory support and other measures are crucial alongside antibiotics, as recommended by the American Thoracic Society 3
Using steroids routinely - not recommended in standard pneumonia treatment, as stated by the Infectious Diseases Society of America 3